Rezultati - Tsai, Max
- Showing 1 - 16 results of 16
-
1
-
2
-
3
-
4
-
5
-
6
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects od Wilbraham, Darren, Biglan, Kevin M., Svensson, Kjell A., Tsai, Max, Kielbasa, William
Izdano 2020Text -
7
-
8
-
9
-
10
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor–Positive Allosteric Modulator, in Patients With Parkinson Disease od Wilbraham, Darren, Biglan, Kevin M., Svensson, Kjell A., Tsai, Max, Pugh, Melissa, Ardayfio, Paul, Kielbasa, William
Izdano 2021Text -
11
-
12
-
13
A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationsh... od Goldsmith, Paul, Affinito, John, McCue, Maggie, Tsai, Max, Roepcke, Stefan, Xie, Jinhui, Gertsik, Lev, Macek, Thomas A.
Izdano 2017Text -
14
Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls od Pearlman, Eric M., Wilbraham, Darren, Dennehy, Ellen B., Berg, Paul H., Tsai, Max, Doty, Erin G., Kay, Gary G.
Izdano 2020Text -
15
-
16
An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients od Gilleen, James, Farah, Yakub, Davison, Cate, Kerins, Sarah, Valdearenas, Lorena, Uz, Tolga, Lahu, Gez, Tsai, Max, Ogrinc, Frank, Reichenberg, Avi, Williams, Steve C., Mehta, Mitul A., Shergill, Sukhi S.
Izdano 2018Text